Last update 01 Nov 2024

ADAM proteins

Last update 01 Nov 2024

Basic Info

Synonyms-

Introduction-

Drugs associated with ADAM proteins

INCB003619

Target

ADAM proteins

Mechanism

ADAM proteins inhibitors

Active Org.

Incyte Corp.

Originator Org.

Incyte Corp.

Active Indication

Non-Small Cell Lung Cancer

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

GFC-201

Target

ADAM proteins

Mechanism

ADAM proteins inhibitors

Active Org.

GeneFrontier Corp.

Originator Org.

GeneFrontier Corp.

Active Indication

Neoplasms

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with ADAM proteins

100 Translational Medicine associated with ADAM proteins

0 Patents (Medical) associated with ADAM proteins

Literatures (Medical) associated with ADAM proteins

01 Feb 2024·Heliyon

New insight into the role of the ADAM protease family in breast carcinoma progression

Review

Author: Arjmand, Tahura Fayeghi ; Vahdati, Saeed Niazi ; Navasatli, Sepideh Aliniaye ; Mohammadi Far, Marjan ; Behboudi, Hossein

Protease and adhesion molecules play a very emphasized role in the occurrence or progression of metastasis in many types of cancers. In this context, a molecule that contains both protease and adhesion functions play a crucial role in metastasis. ADAMs (a disintegrin and metalloprotease) are molecules with this special characteristic. Recently, a lot of attention has been attracted to various ADAM molecules and researchers have tried to elucidate the role of ADAMs in breast cancer occurrence and progression. Disrupting ADAMs protease and adhesion capabilities can lead to the discovery of worthy therapeutic targets in breast cancer treatment. In this review, we intend to discuss the mechanism of action of various ADAM molecules, their relation to pathogenic processes of breast cancer, and their potential as possible targets for breast cancer treatment.

03 Apr 2023·Current issues in molecular biology

Role of Some microRNA/ADAM Proteins Axes in Gastrointestinal Cancers as a Novel Biomarkers and Potential Therapeutic Targets-A Review.

Review

Author: Nowakowska-Zajdel, Ewa ; Kalita, Agnieszka ; Sikora-Skrabaka, Magdalena

A review.Gastrointestinal (GI) cancers are some of the most common cancers in the world and their number is increasing.Their etiol. and pathogenesis are still unclear.ADAM proteins are a family of transmembrane and secreted metalloproteinases that play a role in cancerogenesis, metastasis and neoangiogenesis.MicroRNAs are small single-stranded non-coding RNAs that take part in the post-transcriptional regulation of gene expression.Some ADAM proteins can be targets for microRNAs.In this review, we analyze the impact of microRNA/ADAM protein axes in GI cancers.

01 Feb 2023·Cellular Signalling

Multi-targeting TACE/ADAM17 and gamma-secretase of notch signalling pathway in TNBC via drug repurposing approach using Lomitapide

Article

Author: Ghosh, Siddhartha Sankar ; Kandasamy, Thirukumaran ; Sen, Plaboni

The aberrant expression of the Notch signalling pathway genes aids in potentiating the belligerent characteristics of numerous malignancies. Besides imparting abnormal proliferation and metastasis, the Notch also aids in the metabolic reprogramming of tumor cells. Since the activation of the Notch pathway is mediated via TACE/ADAM protease and the γ-secretase complex, hence it is crucial in determining a multi-targeted therapeutic approach to target these major proteases to downregulate the aberrant Notch signalling pathway. In this study, Lomitapide was chosen based on its binding score (-305.108 kJ/mol and - 173.174 kJ/mol) against the crucial proteases, TACE and γ-secretase, respectively. Further, the remarkable antitumor properties of Lomitapide were established on the TNBC cell lines (MDA-MB-231 and MDA-MB-468), along with the EMT-induced MDA-MB-468 cells. Apart from inducing ∼2 to 2.5-fold increase in the cellular ROS levels, Lomitapide treatment induced significant apoptosis, arrested cell cycle progression and reduced sphere and colony forming abilities of the TNBC cells. Differentiated epithelial phenotype with diminished CD44-stem cell marker was also observed upon treatment. Furthermore, reduction of migration potential, decrease in the gene expression profile of the EMT markers, along with downregulation of the Notch signalling genes were evident in the treated TNBC cells. Altogether, the present study attributes the repurposing of Lomitapide as an effective therapeutic agent against the major proteases of the Notch pathway to combat TNBC progression and dissemination.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

ADAM proteins

Basic Info

Related

Analysis